Early nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.

IF 4 2区 医学 Q1 CLINICAL NEUROLOGY
Headache Pub Date : 2025-10-01 Epub Date: 2025-06-25 DOI:10.1111/head.14999
Soohyun Cho, Minjung Seong, Mi Ji Lee
{"title":"Early nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.","authors":"Soohyun Cho, Minjung Seong, Mi Ji Lee","doi":"10.1111/head.14999","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives/background: </strong>Although nimodipine is commonly used to treat reversible cerebral vasoconstriction syndrome (RCVS), its disease-modifying effects are not yet understood. We prospectively investigated the effect of nimodipine and treatment initiation timing on the prevention of worsened vasoconstriction in patients with angiogram-proven RCVS.</p><p><strong>Methods: </strong>In this prospective cohort study, we recruited patients with angiogram-proven RCVS who visited a single headache clinic between June 2019 and November 2021. To evaluate the mean flow velocities (MFVs) of the middle cerebral arteries, patients underwent transcranial Doppler at baseline and were then serially followed up after 10, 20, 30, and 90 days. Oral nimodipine treatment was initiated after the baseline transcranial Doppler study. We estimated the worsening of vasoconstriction using the area of total time spent with MFVs above the baseline value (\"MFV area\").</p><p><strong>Results: </strong>A total of 32 patients (51.5 ± 10.3 years old, 91% female) completed this study. During nimodipine treatment, MFVs gradually decreased in 94% (n = 30/32) of patients (p < 0.001). The MFVs in the early treatment group (<7 days after onset) were lower than the untreated baseline MFVs of the late treatment group (≥7 days) at the same time point after onset (69.8 ± 19.4 vs. 86.1 ± 23.7 cm/s, p = 0.032). Earlier treatment with nimodipine correlated with reduced MFV area (r = 0.37, p = 0.038), and this relationship remained significant after adjustment for covariates (β = 58.46, 95% confidence interval = 2.31-114.62, p = 0.041).</p><p><strong>Conclusion: </strong>Our study shows an independent association between the timing of oral nimodipine administration and exacerbation of cerebral vasoconstriction in patients with RCVS, suggesting that early administration of nimodipine may have a role in mitigating vasoconstriction. A potential disease-modifying role of nimodipine should be tested in future studies using a hypothesis-testing design.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1617-1625"},"PeriodicalIF":4.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497928/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Headache","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/head.14999","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives/background: Although nimodipine is commonly used to treat reversible cerebral vasoconstriction syndrome (RCVS), its disease-modifying effects are not yet understood. We prospectively investigated the effect of nimodipine and treatment initiation timing on the prevention of worsened vasoconstriction in patients with angiogram-proven RCVS.

Methods: In this prospective cohort study, we recruited patients with angiogram-proven RCVS who visited a single headache clinic between June 2019 and November 2021. To evaluate the mean flow velocities (MFVs) of the middle cerebral arteries, patients underwent transcranial Doppler at baseline and were then serially followed up after 10, 20, 30, and 90 days. Oral nimodipine treatment was initiated after the baseline transcranial Doppler study. We estimated the worsening of vasoconstriction using the area of total time spent with MFVs above the baseline value ("MFV area").

Results: A total of 32 patients (51.5 ± 10.3 years old, 91% female) completed this study. During nimodipine treatment, MFVs gradually decreased in 94% (n = 30/32) of patients (p < 0.001). The MFVs in the early treatment group (<7 days after onset) were lower than the untreated baseline MFVs of the late treatment group (≥7 days) at the same time point after onset (69.8 ± 19.4 vs. 86.1 ± 23.7 cm/s, p = 0.032). Earlier treatment with nimodipine correlated with reduced MFV area (r = 0.37, p = 0.038), and this relationship remained significant after adjustment for covariates (β = 58.46, 95% confidence interval = 2.31-114.62, p = 0.041).

Conclusion: Our study shows an independent association between the timing of oral nimodipine administration and exacerbation of cerebral vasoconstriction in patients with RCVS, suggesting that early administration of nimodipine may have a role in mitigating vasoconstriction. A potential disease-modifying role of nimodipine should be tested in future studies using a hypothesis-testing design.

Abstract Image

Abstract Image

Abstract Image

早期尼莫地平治疗可逆性脑血管收缩综合征:一系列经颅多普勒研究。
目的/背景:虽然尼莫地平常用于治疗可逆性脑血管收缩综合征(RCVS),但其疾病改善作用尚不清楚。我们前瞻性地研究了尼莫地平和开始治疗时间对血管造影证实的RCVS患者血管收缩恶化的预防作用。方法:在这项前瞻性队列研究中,我们招募了2019年6月至2021年11月期间就诊过一家头痛诊所的血管造影证实的RCVS患者。为了评估大脑中动脉的平均血流速度(MFVs),患者在基线时接受经颅多普勒检查,然后在10、20、30和90天后进行连续随访。经颅多普勒基线研究后开始口服尼莫地平治疗。我们使用MFV超过基线值的总时间面积(“MFV面积”)来估计血管收缩的恶化。结果:32例患者(51.5±10.3岁,91%为女性)完成了本研究。在尼莫地平治疗期间,94% (n = 30/32)的患者MFVs逐渐下降(p)。结论:本研究显示口服尼莫地平给药时间与RCVS患者脑血管收缩加剧之间存在独立关联,提示早期给药尼莫地平可能具有缓解血管收缩的作用。尼莫地平的潜在疾病调节作用应在未来的研究中使用假设检验设计进行检验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Headache
Headache 医学-临床神经学
CiteScore
9.40
自引率
10.00%
发文量
172
审稿时长
3-8 weeks
期刊介绍: Headache publishes original articles on all aspects of head and face pain including communications on clinical and basic research, diagnosis and management, epidemiology, genetics, and pathophysiology of primary and secondary headaches, cranial neuralgias, and pains referred to the head and face. Monthly issues feature case reports, short communications, review articles, letters to the editor, and news items regarding AHS plus medicolegal and socioeconomic aspects of head pain. This is the official journal of the American Headache Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信